Evaluation of reverse hybridization assay for detecting fluoroquinolone and kanamycin resistance in multidrug-resistance Mycobacterium tuberculosis clinical isolates

Tuberculosis and Respiratory Diseases

Volumn 72, Issue 1, 2012, Pages 44-49

  Park, Chinsu ^a   Sung, Nackmoon ^a   Hwang, Soohee ^a   Jeon, Jaehyun ^a   Won, Youngsub ^a   Min, Jinhong ^a   Kim, Cheon Tae ^a   Kang, Hyungseok ^a  

^a Masan National Hospital   (South Korea)

Author keywords

Drug resistance, microbial; Fluoroquinolones; Kanamycin; Mutation; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACILLUS; BACTERIUM CULTURE; BACTERIUM ISOLATE; DNA EXTRACTION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; TUBERCULOSIS;

EID: 84863182914     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2012.72.1.44     Document Type: Article

References (23)

1. Multidrug and extensively drug-resistant Tb (m/xdr-Tb): 2010 global report on surveillance and response. Geneva, Switzerland: World Health Organization; 2010.
2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6. (Pubitemid 46732647)
3. Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E, et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001-2005. Tuberc Respir Dis 2008;64:187-93. (Pubitemid 351944596)
4. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
5. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, Switzerland: World Health Organization; 2008.
6. Joh JS, Lee CH, Lee JE, Park YK, Bai GH, Kim EC, et al. The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results. J Korean Med Sci 2007;22:26-9.
7. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005;525:564-9. (Pubitemid 40331189)
8. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-80. (Pubitemid 24114017)
9. Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004;48:596-601. (Pubitemid 38141721)
10. Giannoni F, Iona E, Sementilli F, Brunori L, Pardini M, Migliori GB, et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:2928-33. (Pubitemid 40917612)
11. Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, Mizuguchi Y, et al. Detection of kanamydn-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 1998;36:1220-5. (Pubitemid 28208002)
12. Krüüner A, Jureen P, Levina K, Ghebremichael S, Hoffner S. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:2971-3. (Pubitemid 37040278)
13. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:3192-7. (Pubitemid 41060560)
14. Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009;53:5064-8.
15. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969;41:21-43.
16. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50. (Pubitemid 23083244)
17. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 1995;8:496-514.
18. Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 2004;9:975-94. (Pubitemid 39043767)
19. Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-6. (Pubitemid 15133592)
20. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50.
21. Montera C, Mateu G, Rodriguez R, Takiff H. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 2001;45:3387-92.
22. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003;3:249-82.
23. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-72.